MATERIALS AND METHODS Subjects. Study subjects were selected from a cohort of HIV-1-infected pregnant women enrolled in the Ariel Project for the Prevention of Transmission of HIV from Mother to Infant and monitored throughout their pregnancies. The Ariel cohort enrolled mothers at the seven clinical sites located in Fort Lauderdale, Fla.; Newark, N.J.; Houston, Tex.; Bronx, N.Y.; Stamford, Conn.; Worcester, Mass.; and New Orleans, La. Subjects included in this study were prospectively monitored at the Houston, Bronx, Worcester, and Fort Lauderdale clinical sites. The characteristics of the Ariel cohort are described elsewhere ( 6). Among the total of 204 HIV-1-infected pregnant women enrolled in the study, we selected 3 of the 8 women who infected their infants during gestation and 8 of the 185 women who did not, based on sample availability and the detection of an immunodominant CTL response. The numbers of copies of virion-associated RNA per milliliter of plasma were quantified for each woman at the time peripheral blood was obtained for T-cell cloning, a visit corresponding to the time of delivery, by the AMPLICOR HIV-1 Monitor Test (Roche Diagnostic Systems, Inc., Branchburg, N.J.) as instructed by the manufacturer. The infection status of the infants born to these mothers was determined by the presence of HIV-1 proviral DNA in peripheral blood mononuclear cells by using a PCR-based assay and by viral coculture at delivery and at regular intervals thereafter. Cell lines. Epstein-Barr virus-transformed B-lymphoblastoid cell lines (B-LCL) were established from the peripheral blood mononuclear cells (PBMC) of each subject and maintained as previously described ( 57) in RPMI 1640 medium (Sigma, St. Louis, Mo.) containing 20% heat-inactivated fetal calf serum (Sigma). RPMI 1640 medium used for all cell lines was supplemented with l-glutamine (2 mM), penicillin (50 U/ml), streptomycin (50 μg/ml), and HEPES (10 mM). Additional allogeneic B-LCL used in HLA restriction experiments were established and maintained in a similar fashion. HLA class I typing. HLA typing was performed by using a standard lymphocytotoxicity assay and confirmed in some cases with a PCR-based allele-specific molecular typing assay ( 24). Recombinant vaccinia virus constructs. Recombinant vaccinia viruses expressing the full-length HIV-1 gp160 gene (VPE16) as well as serial truncations of the HIV-1 envelope gene (VPE17-22) were provided by P. Earl and B. Moss. Recombinant vaccinia viruses expressing HIV-1 p55gag (vAbT141), p24gag (vAbT286), p17gag (vAbT228), HIV-1 Pol (vAbT204), HIV-1 Nef (vT23), and wild-type control (NYCBH) were provided by Therion Biologics (Cambridge, Mass.). Stocks of recombinant vaccinia viruses were adjusted to approximately 109 PFU/ml, stored in aliquots at −80°C, and thawed immediately prior to use. HIV-1 peptide synthesis. Synthetic peptides corresponding to the HIV-1 HXB10 sequence ( 26), consisting of a series of peptides 25 amino acids in length that overlapped by 8 amino acids, were synthesized and purified by Multiple Peptide Systems (San Diego, Calif.) as described previously ( 31). Peptides were synthesized as COOH-terminal amides unless otherwise noted. Smaller peptides of 8 to 15 amino acids used for fine mapping were synthesized as free acids on an automated peptide sequencer (Applied Biosystems model 420A). Lyophilized peptides were reconstituted at 2 mg/ml in sterile distilled water with 10% dimethyl sulfoxide (Sigma) and 1% 1 mM dithiothreitol (Sigma). Isolation of HIV-1-specific CTL clones and lines. CTL clones were isolated and maintained as described previously ( 57). Briefly, PBMC were obtained by separation of whole blood on a Ficoll-sodium diatrozoate gradient (Sigma) and were plated at concentrations ranging from 10 to 100 cells per well of a 96-well plate. Cells were maintained with a feeder solution containing 10 6 irradiated allogeneic PBMC per ml from uninfected subjects in RPMI 1640 with 10% heat-inactivated fetal calf serum supplemented with 100 U of human recombinant interleukin-2 (Hoffmann-La Roche, Nutley, N.J.) per ml. The CD3-specific monoclonal antibody (MAb) 12F6 ( 62) was added at a final concentration of 0.1 μg/ml to stimulate T-cell proliferation. Cells from wells demonstrating growth were restimulated further as previously described ( 32) and then tested for cytolytic activity against autologous target cells infected with recombinant vaccinia viruses expressing HIV-1 genes approximately 4 to 6 weeks after the initial cloning. T-cell clones exhibiting HIV-1-specific CTL activities were restimulated every 14 to 21 days with anti-CD3 MAb and irradiated allogeneic PBMC. Flow cytometric analysis. Cells were incubated with fluorescent probe-conjugated anti-CD3/anti-CD4, anti-CD3/anti-CD8, and anti-mouse immunoglobulin G2b (IgG2b)/IgG1 MAbs as controls (Coulter Electronics, Hialeah, Fla.), singly or in combination. Samples of stained cells were analyzed with a FACScan flow cytometer (Becton Dickinson and Co., Mountain View, Calif.) as described previously ( 32). Cytotoxicity assay. Target cells consisted of B-LCL infected with recombinant vaccinia viruses or preincubated with synthetic HIV-1 peptides. Target B-LCL were infected with recombinant vaccinia virus as previously described ( 59), and labeled with 65 to 100 μCi of [ 51CrO 4] Na 2 (New England Nuclear, North Billerica, Mass.) overnight, and then washed three times with RPMI 1640 medium. Peptide-sensitized target cells were obtained by incubating 2 × 10 6 to 3 × 10 6 B-LCL with peptide for 60 min during 51Cr labeling. Cytolytic activity was determined in a standard 4-h 51Cr release assay using U-bottom microtiter plates containing 5 × 10 3 targets per well. Assays were performed in duplicate. Supernatant fluids were harvested onto 96-well plates containing solid scintillate, allowed to dry overnight, and then counted in a TopCount microplate scintillation counter (Packard Instrument Co., Meriden, Conn.). Maximum release was determined by lysis of targets in detergent (1% Triton X-100; Sigma). Percent lysis was determined as 100 × [(experimental release − spontaneous release)/(maximum release − spontaneous release)]. Spontaneous release values were less than 30% of maximal release for all reported assays. In vitro amplification of epitope-encoding regions and viral sequence analysis. To explore the relationship between CTL recognition or escape and genetic diversity within class I MHC-restricted epitopes, we assessed the diversity of viral sequences within these individuals by examining proviral sequences spanning selected fragments of the gag, pol, env, and nef coding regions. PCR was used to amplify proviral DNA at endpoint dilution in cells obtained from the index visit near the time of parturition. In some cases only short fragments spanning just the regions of interest were sequenced, but in other cases longer sequences were generated, and those sequences were incorporated into the phylogenetic analysis shown in Fig. 3. The positions of the oligonucleotide primers are numbered according to the HXB2 isolate in the human retroviruses and AIDS database ( 37). LTRF1.1 (nucleotides 518 to 542; 5′-TAAGCCTCAATAAAGCTTGCCTTG-3′), LTRF2.1 (nucleotides 574 to 542; 5′-TGTGACTCTGGTA[A/G]CTAGAGATCCC-3′), LTRF3.1 (nucleotides 626 to 650; 5′-TCTCTAGCAGTGCGCCCCGAACAGG-3′), VACGAGR1 (nucleotides 2314 to 2338; 5′-TCTGCTCCTGTATCTAATAGAGCTT-3′), VACGAGR2 (nucleotides 2375 to 2399; 5′-TCC[C/T]CCTATCATTTTTGGTTTCCAT-3′), VACGAGR3 (nucleotides 2468 to 2492; 5′-TGTAGGTCCTACTAATACTGTACCT-3′), and CTLPOLF1 (nucleotides 2318 to 2341; 5′-TCTATTAGATACAGGAGCAGATGA-3′) are the gag amplification primers. The outer sets of gag amplification primers and their amplicon sizes are LTRF1.1 and VACGAGR3 (1,974 bp), LTRF1.1 and VACGAGR2 (1,881 bp), LTRF2.1 and VACGAGR3 (1,918 bp), and LTRF2.1 and VACGAGR2 (1,825 bp). The inner sets of gag amplification primers and their amplicon sizes are LTRF2.1 and VACGAGR2 (1,825 bp), LTRF2.1 and VACGAG1 (1,764 bp), LTRF3.1 and VACGAGR1 (1,712 bp), and LTRF3.1 and VACGAGR2 (1,974 bp). CTLPOLF2 (nucleotides 2391 to 2415; 5′-TAGG[G/A]GGAATTGGAGGTTTTATCA-3′), CTLPOLF3 (nucleotides 2467 to 2490; 5′-TAGGTACAGTATTAGTAGGACCTA-3′), CTLPOLR1 (nucleotides 4060 to 4083; 5′-TATCTGGTTGTGCTTGAATGATTC-3′), CTLPOLR2 (nucleotides 4321 to 4344; 5′-TGGCTACTATTTCTTTTGCTACTA-3′), and CTLPOLR3 (nucleotides 4649 to 4673; 5′-TTGACTTTGGGGATTGTAGGGAAT-3′) are the pol amplification primers. The outer sets of pol amplification primers and their amplicon sizes are CTLPOLF1 and CTLPOLR3 (2,355 bp), CTLPOLF1 and CTLPOLR2 (2,355 bp), CTLPOLF2 and CTLPOLR3 (2,282 bp), and CTLPOLF2 and CTLPOLR2 (1,953 bp). The outer sets of pol amplification primers and their amplicon sizes are CTLPOLF2 and CTLPOLR2 (1,953 bp), CTLPOLF2 and CTLPOLR2 (1,953 bp), CTLPOLF2 and CTLPOLR1 (1,692 bp), CTLPOLF3 and CTLPOLR2 (1,877 bp), and CTLPOLF3 and CTLPOLR1 (1,616 bp). KKE5P3 (nucleotides 6189 to 6213; 5′-GCGACCCGGGTTGATAGA[C/A]TAA[T/G]AGAAAGAGCAGA-3′) and KKE3P1 (nucleotides 8809 to 8833; 5′-GCGAGAATTCATCC[C/A]AC[T/C]A[C/T]ACTAC[T/G]TTTTGACCA-3′) are the env amplification primers. The input DNA molecules were quantified by PCR using serial fivefold dilutions. Twenty 5-μl samples of endpoint-diluted DNA were amplified in a 100-μl reaction mix containing 0.2 μM outer primer pair as described elsewhere ( 22). PCR was performed with a Perkin-Elmer/Cetus 9600 automated thermal cycler programmed for for 35 cycles at 98°C for 10 s, 50°C for 30 s, and 72°C for 3 min, with a final extension at 72°C for 10 min. A 5-μl sample was reamplified from each reaction in a 100-μl reaction mix containing 0.2 μM inner primer pair by means of the same cycle profile as specified above. HIV-1-negative cell DNA and reagent controls were run in parallel ( 40). PCR product DNA was resolved by electrophoresis on a 1.0% NuSieve GTG gel (FMC BioProducts). The correctly sized band was purified from the agarose gel by electroelution using gene capsules (Geno Technologies, Inc.) and inserted into pCR 2.1 (Invitrogen), using the principles of TA cloning. One microgram of the double-stranded DNA template was sequenced in both forward and reverse directions, using the respective gag, pol, and env internal primers with the use of dideoxynucleoside triphosphates (Dye-Deoxy terminators) and analyzed with a model 377 sequencing system (Applied Biosystems) as described elsewhere ( 22). ![FIG. 3 FIG. 3](picrender.fcgi?artid=104176&blobname=jv0591550003.gif) | FIG. 3Phylogenetic reconstruction of viral sequences from peripheral blood. The trees shown were generated by the neighbor-joining method using the maximum-likelihood method for calculating distances in the options provided by the neighbor program in the PHYLIP (more ...) |
Phylogenetic reconstruction and statistical analysis. The sequences were hand aligned by using a modified version of the MASE program ( 20). The sequences were gap stripped ( 42), and phylogenetic analysis was done by the neighbor-joining, bootstrap, and maximum-likelihood methods from the PHYLIP package ( 21). Statistics were done with the Splus package, version 3.4 (MathSoft, Inc.). Nucleotide sequence accession numbers. The viral sequences reported in this study are available in GenBank, under accession no. AF121459 to AF121669. |
REFERENCES 1. Back, N K; Smit, L; Schutten, M; Nara, P L; Tersmette, M; Goudsmit, J. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J Virol. 1993;67:6897–6902. [PubMed]2. Bertoletti, A; Sette, A; Chisari, F V; Penna, A; Levrero, M; De Carli, M; Fiaccadori, F; Ferrari, C. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature. 1994;369:407–410. [PubMed]3. Borrow, P; Lewicki, H; Hahn, B H; Shaw, G M; Oldstone, M B. Virus-specific CD8 + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68:6103–6110. [PubMed]4. Borrow, P; Lewicki, H; Wei, X; Horwitz, M S; Peffer, N; Meyers, H; Nelson, J A; Gairin, J E; Hahn, B H; Oldstone, M B; Shaw, G M. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med. 1997;3:205–211. [PubMed]5. Bryson, Y J. Perinatal HIV-1 transmission: recent advances and therapeutic interventions. AIDS. 1996;10:S33–S42. 6. Cao, Y; Krogstad, P; Korber, B T; Koup, R A; Muldoon, M; Macken, C; Song, J L; Jin, Z; Zhao, J Q; Clapp, S; Chen, I S; Ho, D D; Ammann, A J. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med. 1997;3:549–552. [PubMed]7. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid Mortal Weekly Rep. 1992;41:RR–17. 8. Clerici, M; Shearer, G M. A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993;14:107–111. [PubMed]9. Clerici, M; Sison, A V; Berzofsky, J A; Rakusan, T A; Brandt, C D; Ellaurie, M; Villa, M; Colie, C; Venzon, D J; Sever, J L; Shearer, G M. Cellular immune factors associated with mother-to-infant transmission of HIV. AIDS. 1993;7:1427–1433. [PubMed]10. Coffin, J M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483–489. [PubMed]11. Coll, O; Hernandez, M; Boucher, C A; Fortuny, C; de Tejada, B M; Canet, Y; Caragol, I; Tijnagel, J; Bertran, J M; Espanol, T. Vertical HIV-1 transmission correlates with a high maternal viral load at delivery. J Acquired Immune Defic Syndr Hum Retrovirol. 1997;14:26–30. [PubMed]12. Collins, K L; Chen, B K; Kalams, S A; Walker, B D; Baltimore, D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature. 1998;391:397–401. [PubMed]13. Connor, E M; Sperling, R S; Gelber, R; Kiselev, P; Scott, G; O’Sullivan, M J; VanDyke, R; Bey, M; Shearer, W; Jacobson, R L; Jimenez, E; O’Neill, E; Bazin, B; Delfraissy, J; Culnane, M; Coombs, R; Elkins, M; Moye, J; Stratton, P; Balsley, J. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173–1180. [PubMed]14. Devash, Y; Calvelli, T A; Wood, D G; Reagan, K J; Rubinstein, A. Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc Natl Acad Sci USA. 1990;87:3445–3449. [PubMed]15. DiBrino, M; Parker, K C; Shiloach, J; Knierman, M; Lukszo, J; Turner, R V; Biddison, W E; Coligan, J E. Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides. Proc Natl Acad Sci USA. 1993;90:1508–1512. [PubMed]16. Dickover, R E; Garratty, E M; Herman, S A; Sim, M S; Plaeger, S; Boyer, P J; Keller, M; Deveikis, A; Stiehm, E R; Bryson, Y J. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. JAMA. 1996;275:599–605. [PubMed]17. Ehrnst, A; Lindgren, S; Belfrage, E; Sonnerborg, A; Dictor, M; Johansson, B; Bohlin, A B. Intrauterine and intrapartum transmission of HIV. Lancet. 1992;339:245–246. [PubMed]18. Ehrnst, A; Lindgren, S; Dictor, M; Johansson, B; Sonnerborg, A; Czajkowski, J; Sundin, G; Bohlin, A B. HIV in pregnant women and their offspring: evidence for late transmission. Lancet. 1991;338:203–207. [PubMed]19. Fang, G; Burger, H; Grimson, R; Tropper, P; Nachman, S; Mayers, D; Weislow, O; Moore, R; Reyelt, C; Hutcheon, N; Baker, D; Weiser, B. Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA. 1995;92:12100–12104. [PubMed]20. Faulkner, D V; Jurka, J. Multiple aligned sequence editor (MASE). Trends Biochem Sci. 1988;13:321–322. [PubMed]21. Felsenstein, J. Phylogeny Inference Package (PHYLIP), version 3.5c. Seattle, Wash: Department of Genetics, University of Washington; 1993. 22. Ganeshan, S; Dickover, R E; Korber, B T; Bryson, Y J; Wolinsky, S M. Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease. J Virol. 1997;71:663–677. [PubMed]23. Garrity, R R; Rimmelzwaan, G; Minassian, A; Tsai, W P; Lin, G; de Jong, J J; Goudsmit, J; Nara, P L. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol. 1997;159:279–289. [PubMed]24. Goulder, P J; Phillips, R E; Colbert, R A; McAdam, S; Ogg, G; Nowak, M A; Giangrande, P; Luzzi, G; Morgan, B; Edwards, A; McMichael, A J; Rowland-Jones, S. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med. 1997;3:212–217. [PubMed]25. Goulder, P J; Sewell, A K; Lalloo, D G; Price, D A; Whelan, J A; Evans, J; Taylor, G P; Luzzi, G; Giangrande, P; Phillips, R E; McMichael, A J. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med. 1997;185:1423–1433. [PubMed]26. Hahn, B H; Shaw, G M; Arya, S K; Popovic, M; Gallo, R C; Wong-Staal, F. Molecular cloning and characterization of the HTLV-III virus associated with AIDS. Nature. 1984;312:166–169. [PubMed]27. Harrer, T; Harrer, E; Kalams, S A; Barbosa, P; Trocha, A; Johnson, R P; Elbeik, T; Feinberg, M B; Buchbinder, S P; Walker, B D. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol. 1996;156:2616–2623. [PubMed]28. Hay, C. M., D. J. Ruhl, N. O. Basgoz, C. C. Wilson, J. M. Billingsley, M. P. DePasquale, R. T. D’Aquila, and B. D. Walker. Lack of viral escape and defective in vivo activation of HIV-1-specific CTL in rapidly progressive HIV-1 infection. Submitted for publication. 29. Huang, Y; Paxton, W A; Wolinsky, S M; Neumann, A U; Zhang, L; He, T; Kang, S; Ceradini, D; Jin, Z; Yazdanbakhsh, K; Kunstman, K; Erickson, D; Dragon, E; Landau, N R; Phair, J; Ho, D D; Koup, R A. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;2:1240–1243. [PubMed]30. Husson, R N; Lan, Y; Kojima, E; Venzon, D; Mitsuya, H; McIntosh, K. Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype. J Pediatr. 1995;126:865–871. [PubMed]31. Johnson, R P; Trocha, A; Buchanan, T M; Walker, B D. Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J Virol. 1993;67:438–445. [PubMed]32. Johnson, R P; Trocha, A; Yang, L; Mazzara, G P; Panicali, D L; Buchanan, T M; Walker, B D. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol. 1991;147:1512–1521. [PubMed]33. Kalams, S A; Johnson, R P; Dynan, M J; Hartman, K E; Harrer, T; Harrer, E; Trocha, A K; Blattner, W A; Buchbinder, S P; Walker, B D. T cell receptor usage and fine specificity of human immunodeficiency virus 1-specific cytotoxic T lymphocyte clones: analysis of quasispecies recognition reveals a dominant response directed against a minor in vivo variant. J Exp Med. 1996;183:1669–1679. [PubMed]34. Khouri, Y F; McIntosh, K; Cavacini, L; Posner, M; Pagano, M; Tuomala, R; Marasco, W A. Vertical transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies. J Clin Investig. 1995;95:732–737. [PubMed]35. Klein, M R; van Baalen, C A; Holwerda, A M; Kerkhof Garde, S R; Bende, R J; Keet, I P; Eeftinck-Schattenkerk, J K; Osterhaus, A D; Schuitemaker, H; Miedema, F. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med. 1995;181:1365–1372. [PubMed]36. Klenerman, P; Rowland-Jones, S; McAdam, S; Edwards, J; Daenke, S; Lalloo, D; Koppe, B; Rosenberg, W; Boyd, D; Edwards, A; Giangrande, P; Phillips, R E; McMichael, A J. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature. 1994;369:403–407. [PubMed]37. Korber B T, Brander C, Haynes B F, Moore J P, Koup R, Walker B D. , editors. HIV molecular immunology database 1997. Los Alamos, N.Mex: Theoretical Biology and Biophysics, Los Alamos National Laboratory; 1997. 38. Korber, B T; Kunstman, K J; Patterson, B K; Furtado, M; McEvilly, M M; Levy, R; Wolinsky, S M. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol. 1994;68:7467–7481. [PubMed]39. Koup, R A; Safrit, J T; Cao, Y; Andrews, C A; McLeod, G; Borkowsky, W; Farthing, C; Ho, D D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68:4650–4655. [PubMed]40. Kwok, S; Higuchi, R. Avoiding false positives with PCR. Nature. 1989;339:237–238. [PubMed]41. Landesman, S H; Kalish, L A; Burns, D N; Minkoff, H; Fox, H E; Zorrilla, C; Garcia, P; Fowler, M G; Mofenson, L; Tuomala, R. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. N Engl J Med. 1996;334:1617–1623. [PubMed]42. Learn, G H, Jr; Korber, B T; Foley, B; Hahn, B H; Wolinsky, S M; Mullins, J I. Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol. 1996;70:5720–5730. [PubMed]43. Lu, Z; Berson, J F; Chen, Y; Turner, J D; Zhang, T; Sharron, M; Jenks, M H; Wang, Z; Kim, J; Rucker, J; Hoxie, J A; Peiper, S C; Doms, R W. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci USA. 1997;94:6426–6431. [PubMed]44. Luzuriaga, K; McQuilken, P; Alimenti, A; Somasundaran, M; Hesselton, R; Sullivan, J L. Early viremia and immune responses in vertical human immunodeficiency virus type 1 infection. J Infect Dis. 1993;167:1008–1013. [PubMed]45. Mofenson, L M. Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. Acta Paediatr Suppl. 1997;421:1–9. [PubMed]46. Mulder-Kampinga, G A; Simonon, A; Kuiken, C L; Dekker, J; Scherpbier, H J; van de Perre, P; Boer, K; Goudsmit, J. Similarity in env and gag genes between genomic RNAs of human immunodeficiency virus type 1 (HIV-1) from mother and infant is unrelated to time of HIV-1 RNA positivity in the child. J Virol. 1995;69:2285–2296. [PubMed]47. Peckham, C; Gibb, D. Mother-to-child transmission of the human immunodeficiency virus. N Engl J Med. 1995;333:298–302. [PubMed]48. Phillips, R E; Rowland-Jones, S; Nixon, D F; Gotch, F M; Edwards, J P; Ogunlesi, A O; Elvin, J G; Rothbard, J A; Bangham, C R; Rizza, C R; McMichael, A J. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature. 1991;354:453–459. [PubMed]49. Price, D A; Goulder, P J; Klenerman, P; Sewell, A K; Easterbrook, P J; Troop, M; Bangham, C R; Phillips, R E. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA. 1997;94:1890–1895. [PubMed]50. Rammensee, H G; Friede, T; Stevanoviic, S. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995;41:178–228. [PubMed]51. Rinaldo, C; Huang, X L; Fan, Z F; Ding, M; Beltz, L; Logar, A; Panicali, D; Mazzara, G; Liebmann, J; Cottrill, M; Gupta, P. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol. 1995;69:5838–5842. [PubMed]52. Robertson, C A; Mok, J Y; Froebel, K S; Simmonds, P; Burns, S M; Marsden, H S; Graham, S. Maternal antibodies to gp120 V3 sequence do not correlate with protection against vertical transmission of human immunodeficiency virus. J Infect Dis. 1992;166:704–709. [PubMed]53. Rossi, P; Moschese, V; Broliden, P A; Fundaro, C; Quinti, I; Plebani, A; Giaquinto, C; Tovo, P A; Ljunggren, K; Rosen, J; Wigzell, H; Jondal, M; Wahren, B. Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc Natl Acad Sci USA. 1989;86:8055–8058. [PubMed]54. Rowland-Jones, S L; Nixon, D F; Aldhous, M C; Gotch, F; Ariyoshi, K; Hallam, N; Kroll, J S; Froebel, K; McMichael, A. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet. 1993;341:860–861. [PubMed]55. Scarlatti, G; Leitner, T; Halapi, E; Wahlberg, J; Marchisio, P; Clerici-Schoeller, M A; Wigzell, H; Fenyo, E M; Albert, J; Uhlen, M; Rossi, P. Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci USA. 1993;90:1721–1725. [PubMed]56. Sperling, R S; Shapiro, D E; Coombs, R W; Todd, J A; Herman, S A; McSherry, G D; O’Sullivan, M J; Van Dyke, R B; Jimenez, E; Rouzioux, C; Flynn, P M; Sullivan, J L. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1996;335:1621–1629. [PubMed]57. Walker, B D; Flexner, C; Birch-Limberger, K; Fisher, L; Paradis, T J; Aldovini, A; Young, R; Moss, B; Schooley, R T. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 1989;86:9514–9518. [PubMed]58. Weiser, B; Nachman, S; Tropper, P; Viscosi, K H; Grimson, R; Baxter, G; Fang, G; Reyelt, C; Hutcheon, N; Burger, H. Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Natl Acad Sci USA. 1994;91:8037–8041. [PubMed]59. Wilson, C C; Kalams, S A; Wilkes, B M; Ruhl, D J; Gao, F; Hahn, B H; Hanson, I C; Luzuriaga, K; Wolinsky, S; Koup, R; Buchbinder, S P; Johnson, R P; Walker, B D. Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognition. J Virol. 1997;71:1256–1264. [PubMed]59a. Wilson, C. C., and B. D. Walker. Unpublished data. 60. Wolinsky, S M; Korber, B T; Neumann, A U; Daniels, M; Kunstman, K J; Whetsell, A J; Furtado, M R; Cao, Y; Ho, D D; Safrit, J T. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science. 1996;272:537–542. [PubMed]61. Wolinsky, S M; Wike, C M; Korber, B T; Hutto, C; Parks, W P; Rosenblum, L L; Kunstman, K J; Furtado, M R; Munoz, J L. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science. 1992;255:1134–1137. [PubMed]62. Wong, J T; Colvin, R B. Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J Immunol. 1987;139:1369–1374. [PubMed]63. Yang, O O; Kalams, S A; Trocha, A; Cao, H; Luster, A; Johnson, R P; Walker, B D. Suppression of human immunodeficiency virus type 1 replication by CD8 + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol. 1997;71:3120–3128. [PubMed] |